The DNTTIP1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population for loss-of-function studies of DNTTIP1 in a human non-small cell lung cancer model. This heterogeneous pool of NCI-H1299 cells carries targeted disruptions in the DNTTIP1 locus, enabling gene function investigation without clonal selection biases. The polyclonal format maintains population heterogeneity while ensuring DNTTIP1 protein depletion for bulk biochemical, functional, and genomic assays.
The NCI-H1299 host line, derived from a lymph node metastasis of a lung carcinoma from a Caucasian male, is a widely used model of metastatic non-small cell lung carcinoma. It features aggressive growth and lacks TP53 protein expression, making it valuable for tumor progression, metastasis, and therapy studies. Introducing DNTTIP1 knockout in this background allows dissection of DNTTIP1-dependent processes in a cancer-relevant context, particularly chromatin regulation and cell proliferation.
DNTTIP1 is a subunit of the NuA4 histone acetyltransferase complex, which acetylates histones H4 and H2A to promote chromatin relaxation and transcriptional activation. Within the complex, EP400 and TRRAP serve as scaffolds, RUVBL1/2 provide ATPase activity, and terminal deoxynucleotidyltransferase (DNTT) interacts directly with DNTTIP1. The complex is recruited by transcription factors downstream of Notch1 signaling, facilitating acetylation-dependent expression of proliferation genes. DNTTIP1 also participates in DNA double-strand break repair, linking chromatin remodeling to genomic stability.
DNTTIP1 disruption in NCI-H1299 cells creates a relevant model to study the impact of NuA4-mediated histone acetylation on malignant phenotypes. Given its metastatic origin, this knockout system is ideal for examining roles in invasion, proliferation, and DNA damage responses. It allows assessment of whether DNTTIP1 loss alters oncogenic transcriptional programs or sensitizes cells to DNA-damaging agents, revealing therapeutic vulnerabilities in non-small cell lung cancer.
These polyclonal knockout cells support diverse applications: Western blotting for DNTTIP1 depletion, cell proliferation and colony formation assays, ChIP-qPCR for histone H4 acetylation changes, RNA-seq for transcriptome profiling, and DNA damage response assays like ??H2AX foci analysis. This versatility makes the product suitable for chromatin biology, cancer research, and drug target validation. For more details, contact Ascent Research.
